Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
List view / Grid view
Filter the results
25 August 2015 | By Victoria White
MorphoSys and Immatics have formed an alliance to generate antibody-based therapeutics against multiple proprietary cancer antigens recognised by T cells...
4 August 2015 | By Victoria White
MorphoSys and G7 Therapeutics have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs)...
8 May 2015 | By Victoria White
MorphoSys has acquired Lanthio Pharma. The acquisition adds novel candidates including a pre-IND candidate for fibrotic diseases to MorphoSys's portfolio...